01:01am UBS capital rules have Swiss stuck between a rock and a hard place RE
12:55am Swiss stocks - Factors to watch on October 19 RE
11:23pm Alcon Gets US FDA Nod for Redness Reliever Eye Drops MT
10-16 Alcon Wins FDA Approval for Brytly Redness Reliever Eye Drops MT
10-16 Alcon Gets FDA Approval for Brytly Eye Drops DJ
10-16 Novartis ends mid-stage Fabhalta trial targeting serious kidney condition RE
10-16 Partners Group Reportedly Stops Hedge Funds from Investing in Portfolio Companies MT
10-16 Novartis' Loss of Exclusivity Continued to Erode Entresto Sales in Q3, RBC Says MT
10-16 UK Government Reportedly Pitched London as Potential New HQ for UBS MT
10-16 London Woos UBS Zonebourse
10-16 Givaudan slips slightly after five straight gains Zonebourse
10-16 UK Government Reportedly Pitched London as Potential New HQ for UBS MT
10-16 Kapteyn: Hot Inflation Raises Risk of Fed Hikes Beyond December MT
10-16 AlphaValue/Baader Europe Downgrades Novartis to Reduce MT
10-16 UK government courted UBS over potential London move - FT AN
10-16 BofA Sees Galderma's $1.5 Billion ZO Skin Health Acquisition as Accretive to FY28 EPS Growth MT
10-16 RBC Revises Zurich Insurance Group EPS Estimates Ahead of Trading Update MT
10-16 FDA approves Roche's Enspryng as an at-home treatment Zonebourse
10-16 Roche Wins US FDA Approval for Enspryng in Thyroid Eye Disease MT
10-16 Roche Gets FDA Approval for Enspryng to Treat Thyroid Eye Disease DJ
10-16 Swiss stocks - Factors to watch on October 16 RE
10-15 Partners Group Trims Workforce in Private Equity Unit Worldwide MT
10-15 Swiss Market Index Holds Gains; Richemont Reportedly in Talks to Join Consortium Bidding for De Beers MT
10-15 Richemont and Signet reportedly interested in acquiring De Beers Zonebourse
10-15 Nestlé Insists on Baby Food Products' Safety Following Texas Lawsuit MT
No results match your criteria